The Eminent Business Executive and Philanthropist Jack Rosen Joins the Board of Directors at BiondVax Pharmaceuticals

Published: Jul 17, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Nes Ziona, Israel – July 17th 2013 – BiondVax announced today that Jack Rosen, current President of the American Jewish Congress, Chairman of the American Council for World Jewry, Inc., and founder and Chief Executive Officer of the successful New York real estate firm, Rosen Partners LLC, has joined BiondVax’s Board of Directors. Since founding Rosen Partners LLC almost 30 years ago, Mr. Rosen has grown his company to become a leader in creating residential, commercial and hotel developments worldwide. In addition, Mr. Rosen currently serves as a Board Director at Fusion Telecommunications International, Inc., New York, NY. His wide array of business interests includes ventures operating throughout the United States, Europe and Asia in healthcare, cosmetics, telecommunications and security. Notably, a long-time advisor to US presidents from both parties, Mr. Rosen has received various appointments including membership of the NASA Advisory Council.

BiondVax’s CEO, Dr. Ron Babecoff, comments: “Mr. Rosen brings to the Board his many years of global business experience and entrepreneurship. BiondVax's universal influenza vaccine represents a new paradigm for influenza pandemic preparedness AHEAD of the next pandemic. I strongly believe that together with Jack Rosen we can revolutionize protection against influenza worldwide."

About BiondVax Pharmaceuticals Ltd

BiondVax is a publicly traded (TASE: BNDX), advanced clinical stage biotech company dedicated to improving global protection against influenza, with its lead product a universal influenza (flu) vaccine called M-001. Influenza (flu) is the most common infectious disease, caused by countless flu strains as the virus mutates unpredictably and frequently. Current seasonal and pandemic/pre-pandemic flu vaccines rely predominantly on triggering immunity to variable viral regions and accordingly are strain-specific. The vaccines are manufactured based on global surveillance each season or to prepare for a predicted pandemic threat and are often mismatched to the emerging flu strains. Therefore there is an urgent need for broadly protective flu vaccines especially in the case of pandemics and this is being addressed by BiondVax.

For further information, please contact:

Sharon Levin

Gelbert- Kahana

Tel: +972 3 607 0567

Mob: +972 54 4860339

BiondVax`s estimates regarding the future development of the vaccine and expected trials with respect to the vaccine are forward looking information based on the information that BiondVax has in its possession today pertaining to the potential of the vaccine`s development. These estimates may not be realized, in whole or in part, and/or may be realized differently than estimated, as a result of different factors, including the failure to reach the objectives of the trials and/or schedules and/or to obtain the necessary funding for the continuation of development of the vaccine as well as other factors which are not within BiondVax's control and the materialization of any of the risk factors detailed in Section 1.23 of BiondVax`s annual report published on March 21, 2013.

Help employers find you! Check out all the jobs and post your resume.

Back to news